Menu
Recruiting NCT03949049

Citicoline as Neuroprotector in Neonates Exposed to Hypoxia

Phase III Interventional Neonatal Hypoxia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Citicoline, Placebo.
Who it may be relevant to
Registry conditions: Neonatal Hypoxia. Basic parameters: up to 1 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial

Overview

Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Detailed description

Efficacy of Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Interventions

  • Drug Citicoline
    Citacoline as neuroprotector
  • Other Placebo
    placebo group

Primary outcome measures

  • number of seizures [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • neonates with hypoxia.

Exclusion criteria

  • hypoxic ischemic encephalopathy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Sherief Abd-Elsalam — Cairo

Publications

  • Salamah A, El Amrousy D, Elsheikh M, Mehrez M. Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial. Ital J Pediatr. 2023 May 12;49(1):55. doi: 10.1186/s13052-023-01452-5. PMID 37173784

Identifiers

NCT: NCT03949049 · neonates tanta

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗